CN104587346A - Lozenge indicated to patients with chronic sinusitis - Google Patents
Lozenge indicated to patients with chronic sinusitis Download PDFInfo
- Publication number
- CN104587346A CN104587346A CN201510068801.6A CN201510068801A CN104587346A CN 104587346 A CN104587346 A CN 104587346A CN 201510068801 A CN201510068801 A CN 201510068801A CN 104587346 A CN104587346 A CN 104587346A
- Authority
- CN
- China
- Prior art keywords
- extract
- weight
- rhizoma
- lozenge
- buccal tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a lozenge indicated to patients with chronic sinusitis. The total composition of the lozenge comprises 3-9% by weight of pharmaceutical ingredients which can kill pyogenic coccus and bacillus, wherein the pharmaceutical ingredients include extracts of rhizoma polygoni cuspidati, radix euphorbiae pekinensis, herba violae, rhizoma et radix notopterygii, rhizoma alpiniae officinarum and radix et rhizoma rhei; in the total composition of the lozenge, emodin takes up no less than 0.01% by weight of the total composition of the lozenge, euphorbon takes up no less than 0.01% by weight of the total composition of the lozenge, flavonoid glycoside takes up no less than 0.01% by weight of the total composition of the lozenge, dihydrooroselol takes up no less than 0.02% by weight of the total composition of the lozenge, methyl cinnamate takes up no less than 0.008% by weight of the total composition of the lozenge, and rheochrysidin takes up no less than 0.03% by weight of the total composition of the lozenge. The lozenge can effectively kill intraoral pathogenic bacteria, and prevent the intraoral pathogenic bacteria from infecting the nasal cavity.
Description
Technical field
The present invention relates to the buccal tablet that a kind of patients with chronic sinusitis is suitable for.
Background technology
Dental care product is indispensable cleaning supplies in people's daily life, and this series products is of a great variety, comprises buccal tablet, dentifrice, cleaning agent for mouth cavity etc., is mainly used in keeping the cleaning of oral cavity, promotes breath freshening, safeguards good oral environment.But up to the present, not yet there is a buccal tablet be suitable for for patients with chronic sinusitis.
Chronic sinusitis is a kind of global common disease, frequently-occurring disease, have a strong impact on the healthy of people, chronic sinusitis affects the quality of life of sufferer, the respiratory tract infection symptom of making patients, severe patient has the possibility causing cranium eye pulmonary lesions, cause vision to change, even infect and to increase the weight of and dead.Chronic sinusitis is a kind of disease needing long-term medical simultaneously, and needs of patients long-term prescription just can make the state of an illness be controlled.At present, the method for the treatment of chronic sinusitis mainly contains the medicament and nasal spray (or drop) medication two kinds that contain antibiotic composition for oral administration, and these two kinds of methods can play the effect killing pathogenic bacterium.
But, research finds, the why cureless major reason of chronic sinusitis be because pathogenic flora can in oral cavity flourish, environment moistening in oral cavity be very applicable to pyococcus (as streptococcus pneumoniae, Hemolytic Type streptococcus, staphylococcus, micrococcus catarrhalis), bacillus (as hemophilus influenza, Bacillus proteus and escherichia coli) flourish.Find that rear food debris easily remains in oral cavity on the feed by great many of experiments and improve good breeding place to pathogenic bacterium, after feed, in a few hours, pathogenic bacterium start amount reproduction.Oral cavity, nasal cavity are cavitys communicated, pathogenic bacterium can be propagated mutually in cavity, existing Therapeutic Method is simple play to nasal cavity pathogenic bacterium the effect killed, non-boil on the nape opposite the mouth intracavity pathogenic bacterium are killed, when nasal cavity pathogenic bacteria is killed, intraoral pathogenic bacterium to nasal cavity repeated infection, can cause the obstinate of chronic sinusitis again.
At present, market not yet there is a kind of buccal tablet for killing pyococcus, bacillus be suitable for for patients with chronic sinusitis.
Summary of the invention
The object of this invention is to provide the buccal tablet that a kind of patients with chronic sinusitis is suitable for, this buccal tablet contains the ingredient killing pyococcus, bacillus, can effectively kill this type of pathogenic bacterium.
The buccal tablet that patients with chronic sinusitis of the present invention is suitable for, include in its buccal tablet total composition weight ratio be 3% ~ 9% there is the ingredient killing pyococcus, bacillus, described ingredient is the extract of Rhizoma Polygoni Cuspidati, the Radix Euphorbiae Pekinensis, Herba Violae, Rhizoma Et Radix Notopterygii, Rhizoma Alpiniae Officinarum, Radix Et Rhizoma Rhei; Composition is detected using emodin as the quality control of Rhizoma Polygoni Cuspidati extract effective ingredient; Euphorbon detects composition as the quality control of Radix Euphorbiae Pekinensis extract effective ingredient; Flavonoid glycoside detects composition as the quality control of Herba Violae extract effective ingredient; Columbianetin detects composition as the quality control of Rhizoma Seu Radix Notopterygii extract effective ingredient; Methyl cinnamate detects composition as the quality control of Rhizoma Alpiniae Officinarum extract effective ingredient; Physcione detects composition as the quality control of Radix Et Rhizoma Rhei extract effective ingredient; In described buccal tablet total composition, emodin is at percentage by weight >=0.01% of the total constituent of buccal tablet, euphorbon is at percentage by weight >=0.01% of the total constituent of buccal tablet, flavonoid glycoside is at percentage by weight >=0.01% of the total constituent of buccal tablet, columbianetin is at percentage by weight >=0.02% of the total constituent of buccal tablet, methyl cinnamate is at percentage by weight >=0.008% of the total constituent of buccal tablet, and physcione is at percentage by weight >=0.03% of the total constituent of buccal tablet.
The buccal tablet that above-mentioned patients with chronic sinusitis is suitable for more specifically scheme can be: the extract of described Rhizoma Polygoni Cuspidati is emodin extract, the extract of the described Radix Euphorbiae Pekinensis is euphorbon extract, the extract of described Herba Violae is flavonoid glycoside extract, the extract of described Rhizoma Et Radix Notopterygii is columbianetin extract, the extract of described Rhizoma Alpiniae Officinarum is methyl cinnamate extract, the extract of described Radix Et Rhizoma Rhei is physcione extract, the usage ratio of these six kinds of Chinese medicine extract is chosen by respective former medicine ratio, the former medicine of Rhizoma Polygoni Cuspidati: the former medicine in the Radix Euphorbiae Pekinensis: the former medicine of Herba Violae: the former medicine of Rhizoma Et Radix Notopterygii: the former medicine of Rhizoma Alpiniae Officinarum: large xanthan medicine=1:1:1:2:1:3.
Below feature and the control effect and mechanism of each component is introduced respectively.
Rhizoma Polygoni Cuspidati: micro-hardship, is slightly cold.Have antibacterial, antivirus action, main component has emodin, 7-acetyl group-2-methoxyl group-6-methyl-8-hydroxyl-1,4-naphthoquinone, and wherein emodin has stronger inhibitory action to pyococcus.
The Radix Euphorbiae Pekinensis: bitter in the mouth, cold in nature.Main component has euphorbon, alkaloid, euphorbia, and wherein euphorbon has inhibitory action to staphylococcus and bacillus pyocyaneus.
Herba Violae: bitter in the mouth, cold in nature.The flavonoid glycoside contained has very strong killing action to staphylococcus aureus, Staphylococcus albus, Bacillus proteus.
Rhizoma Et Radix Notopterygii: bitter in the mouth, warm in nature.Main component is Coumarins compound, and wherein columbianetin effectively can kill hemophilus influenza.
Rhizoma Alpiniae Officinarum: acrid in the mouth, hot in nature.Main component is methyl cinnamate, eugenol, pinene, cadinene, and wherein methyl cinnamate all has antibacterial action to Hemolytic streptococcus, streptococcus pneumoniae, staphylococcus aureus, Staphylococcus albus.
Radix Et Rhizoma Rhei: bitter in the mouth, cold in nature.Main component is for being anthraquinone glycoside, dianthracene ketone glycoside, physcione, and wherein physcione all has killing action to hemophilus influenza, Bacillus proteus and escherichia coli.
Detailed description of the invention
One, the preparation of pathogenic bacterium composition is killed
Emodin extract: euphorbon extract: flavonoid glycoside extract: columbianetin extract: methyl cinnamate extract: physcione extract=1:1:1:2:1:3.
Two, the buccal tablet that patients with chronic sinusitis is suitable for is prepared
The buccal tablet adopting the patients with chronic sinusitis of mentioned component preparation to be suitable for, only needs the processing technology of the raw material of above-mentioned sterilization component buccal tablet routinely to make buccal tablet.
Three, case of illness introduce
Dragon certain, man, 22 years old, is diagnosed as chronic sinusitis (maxillary sinusitis), has the symptom of stream yellow green nasal mucus, headache, upper volume redness.After being hospitalized for treatment, every day, 3 times (after 3 meal feeds) used above-mentioned buccal tablet, and within 14th, check, the state of an illness is clearly better, and upper volume redness disappears, and headache disappears, and watery nasal discharge phenomenon obviously reduces, and within after continual cure the 25th day, is discharged from hospitals upon recovery.
Chapter, man, 45 years old, is diagnosed as chronic sinusitis (chronic sphenoiditis), has the symptom of headache, toothache, upper volume, red swelling of the pharynx.After being hospitalized for treatment, every day, 3 times (after 3 meal feeds) used above-mentioned buccal tablet, within 15th, checked, the state of an illness is clearly better, and upper volume, red swelling of the pharynx disappear, headache, toothache transference cure, watery nasal discharge reduces, and only has be have a small amount of nasal mucus early morning, within after continual cure the 30th day, cures completely and is discharged from hospitals upon recovery.
Remaining certain, man, 16 years old, is diagnosed as the symptom that chronic sinusitis (maxillary sinusitis) has headache, dizziness, stream yellow green nasal mucus, upper volume redness.After being hospitalized for treatment, every day, 3 times (after 3 meal feeds) used above-mentioned buccal tablet, within 10th, checked, upper volume redness alleviates, and dizzy, headache symptom alleviates, and watery nasal discharge reduces, within 12nd, check, upper volume redness disappears, dizzy, headache transference cure, watery nasal discharge obviously reduces, within 20th, check, upper volume redness disappears, dizzy, headache transference cure, watery nasal discharge obviously reduces, and within after continual cure the 30th day, cures completely and is discharged from hospitals upon recovery.
Claims (2)
1. the buccal tablet that a patients with chronic sinusitis is applicable, it is characterized in that: including weight ratio in its buccal tablet total composition is 3% ~ 9% have and kill pyococcus, the ingredient of bacillus, described ingredient is Rhizoma Polygoni Cuspidati, the Radix Euphorbiae Pekinensis, Herba Violae, Rhizoma Et Radix Notopterygii, Rhizoma Alpiniae Officinarum, the extract of Radix Et Rhizoma Rhei, in described buccal tablet total composition, emodin is at percentage by weight >=0.01% of the total constituent of buccal tablet, euphorbon is at percentage by weight >=0.01% of the total constituent of buccal tablet, flavonoid glycoside is at percentage by weight >=0.01% of the total constituent of buccal tablet, columbianetin is at percentage by weight >=0.02% of the total constituent of buccal tablet, methyl cinnamate is at percentage by weight >=0.008% of the total constituent of buccal tablet, physcione is at percentage by weight >=0.03% of the total constituent of buccal tablet.
2. the buccal tablet that patients with chronic sinusitis according to claim 1 is applicable, it is characterized in that: the extract of described Rhizoma Polygoni Cuspidati is emodin extract, the extract of the described Radix Euphorbiae Pekinensis is euphorbon extract, the extract of described Herba Violae is flavonoid glycoside extract, the extract of described Rhizoma Et Radix Notopterygii is columbianetin extract, the extract of described Rhizoma Alpiniae Officinarum is methyl cinnamate extract, the extract of described Radix Et Rhizoma Rhei is physcione extract, the usage ratio of these six kinds of Chinese medicine extract is chosen by respective former medicine ratio, the former medicine of Rhizoma Polygoni Cuspidati: the former medicine in the Radix Euphorbiae Pekinensis: the former medicine of Herba Violae: the former medicine of Rhizoma Et Radix Notopterygii: the former medicine of Rhizoma Alpiniae Officinarum: large xanthan medicine=1:1:1:2:1:3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510068801.6A CN104587346A (en) | 2015-02-10 | 2015-02-10 | Lozenge indicated to patients with chronic sinusitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510068801.6A CN104587346A (en) | 2015-02-10 | 2015-02-10 | Lozenge indicated to patients with chronic sinusitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104587346A true CN104587346A (en) | 2015-05-06 |
Family
ID=53113617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510068801.6A Pending CN104587346A (en) | 2015-02-10 | 2015-02-10 | Lozenge indicated to patients with chronic sinusitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104587346A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922575A (en) * | 2015-05-30 | 2015-09-23 | 李�杰 | Buccal tablet suitable for patients with bronchitis |
| CN107041938A (en) * | 2017-06-23 | 2017-08-15 | 李宝 | A kind of Chinese medicine preparation for killing pyococcus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070813A (en) * | 2013-02-17 | 2013-05-01 | 李宝 | Toothpaste applicable to chronic sinusitis patients |
-
2015
- 2015-02-10 CN CN201510068801.6A patent/CN104587346A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070813A (en) * | 2013-02-17 | 2013-05-01 | 李宝 | Toothpaste applicable to chronic sinusitis patients |
Non-Patent Citations (1)
| Title |
|---|
| 时东彦等: "31种中药体外抑制金黄色葡萄球菌的活性研究", 《医药导报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922575A (en) * | 2015-05-30 | 2015-09-23 | 李�杰 | Buccal tablet suitable for patients with bronchitis |
| CN107041938A (en) * | 2017-06-23 | 2017-08-15 | 李宝 | A kind of Chinese medicine preparation for killing pyococcus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1698750A (en) | Pharyngitis treating Chinese medicine | |
| EP3307293B1 (en) | Formulations for the treatment of disorders of the mouth, throat and respiratory tract | |
| CN103070813A (en) | Toothpaste applicable to chronic sinusitis patients | |
| CN104042515A (en) | Toothpaste suitable for allergic sinusitis patient | |
| CN104027701A (en) | Oral cavity antibacterial spray suitable for anaphylactic rhinitis patients | |
| CN101181208B (en) | Gargle containing natural antibiotics and preparation method thereof | |
| Ambareen et al. | Go green-keep the root canal clean | |
| CN113350440B (en) | Application of traditional Chinese medicine composition in preparation of antibacterial drugs | |
| CN104587346A (en) | Lozenge indicated to patients with chronic sinusitis | |
| CN104523527A (en) | Toothpaste suitable for patient with chronic bronchitis | |
| CN104825367A (en) | Toothpaste capable of treating bronchitis | |
| CN101856491A (en) | Medicinal composition for treating arthritis and leg injuries | |
| CN104258242A (en) | Bactericide applicable to patients suffering from allergic rhinitis | |
| CN105535406A (en) | Traditional Chinese medicine composition for preventing and treating livestock respiratory disease | |
| CN103610841B (en) | A kind of method for the treatment of bamboo rat stomatitis | |
| CN104922575A (en) | Buccal tablet suitable for patients with bronchitis | |
| CN104606610A (en) | Oral buccal tablet for later-period regulation of chronic bronchitis | |
| CN104189291A (en) | Traditional Chinese medicine composition for treating upper respiratory infection | |
| CN102416066B (en) | Chinese medicinal preparation for treating pharynx and larynx oral disease and preparation method thereof | |
| CN101306080B (en) | Elsholtzia spray | |
| CN1966051B (en) | Antivirus medicament for resisting virus | |
| CN102210744A (en) | Anti-virus infection traditional Chinese medicine composition | |
| CN102920718B (en) | The application of phenylethanoid glycoside monomeric compound | |
| CN105853874A (en) | Esophagus bactericide | |
| CN108159342B (en) | Traditional Chinese medicine composition for treating pneumonia of livestock and poultry and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150506 |
|
| WD01 | Invention patent application deemed withdrawn after publication |